Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...

Results are published in the Journal of Clinical Oncology. “With advent of anti-HER2 therapy in metastatic colorectal cancer, the key question for HER2-amplified RAS/BRAFwild-type tumors is who ...

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...

Clinical and molecular characterization of FAP and SPP1 in colorectal cancer (CRC), CALGB (Alliance)/SWOG 80405 and real-world data. This is an ASCO Meeting Abstract from the 2025 ASCO ...

Effectiveness of anti-epidermal growth factor receptor agents in elderly patients (age ≥ 70 years) with RAS wild-type metastatic colorectal cancer: Nationwide real-world data. This is an ASCO Meeting ...

Aspirin use in patients with PI3K-mutated colorectal cancer helped to reduce disease recurrence, highlighting the importance of upfront genomic testing. Adults with primary primary appendiceal ...

Jan. 28, 2025 — A data analysis from a randomized clinical trial for stage 3 colon cancer patients found that patients with evidence of residual cancer in their blood after surgery to remove the ...

The CRCdx RAS mutation detection kit was designed to detect 35 variants of KRAS and NRAS exon 2, 3, and 4 somatic mutations in patients with colorectal cancer. Fam-trastuzumab deruxtecan-nxki was ...

Lunit’s SCOPE HER2 AI model demonstrated an 86.7% accuracy compared to pathologist assessments for HER2 immunohistochemistry (IHC).

FDA approval of PATHWAY HER2 (4B5) test expands diagnostic capabilities for HER2-ultralow metastatic breast cancer, enabling targeted treatment with trastuzumab deruxtecan. HER2-ultralow ...